Fact-checked by Grok 2 weeks ago

Alvogen

Alvogen is a privately owned, US-based pharmaceutical founded in , specializing in the , in-licensing, , and of generic, branded, over-the-counter (OTC), and products worldwide. Built on the 130-year foundation of Pharmaceuticals, the focuses on complex formulations including injectables, inhalation products, and strategic 505(b)(2) offerings, with over 50 products currently on the market and extensive R&D capabilities. Since its inception, Alvogen has expanded rapidly through acquisitions, partnerships, and market entries, launching its first products in 2011 and achieving key milestones such as the first generic patch in 2015 and generic Copaxone in in 2016. In 2015, led an investment to acquire a majority stake, supporting further growth in regions including , , and the . On September 23, 2025, Alvogen sold its operations to Pharmaceutical, creating a leading international specialized generics platform; global operations continue to span multiple continents, with facilities in for biosimilars via its sister company Alvotech and manufacturing sites in and (now under Lotus for activities). Alvogen's portfolio emphasizes treatments in , , disorders, and , including first-to-market generics like Tamiflu capsules and biosimilars such as Inflectra in . Committed to innovation and accessibility, it continues to build a pipeline of high-barrier generics and branded specialties, positioning itself as a key player in the competitive generics industry.

Company overview

Founding and mission

Alvogen was founded in 2009 by , an Icelandic entrepreneur and former CEO of , who sketched the initial on a restaurant . Wessman, who had previously transformed into a global generics leader during his tenure from 1999 to 2008, aimed to build a new pharmaceutical venture leveraging his expertise in the sector. The company's origins trace back to the 2007 acquisition of Pharmaceuticals by the Alvogen Group, which provided a foundational asset with over 130 years of dating to the late . Alvogen's mission centers on developing, in-licensing, manufacturing, and marketing complex , branded, over-the-counter (OTC), , and specialty pharmaceutical products, with a particular emphasis on "difficult-to-make" drugs such as injectables and inhalations. The company seeks to make high-quality, life-changing medicines more affordable and accessible globally, prioritizing innovative approaches to complex formulations that address unmet needs in healthcare. This focus on high-value, challenging products underscores Alvogen's strategy to differentiate in the competitive generics market. Established as a privately owned entity, Alvogen set its initial headquarters in Morristown, New Jersey, USA, to anchor its operations in the U.S. market. Wessman continues to serve as chairman, guiding the company's vision from its inception.

Ownership structure

Alvogen was founded in 2009 by Róbert Wessman, who initially held private ownership of the company. In 2015, a consortium led by CVC Capital Partners and Temasek Holdings acquired a majority stake in Alvogen from Pamplona Capital Management, with Aztiq Pharma—Wessman's investment vehicle—retaining a minority interest; this transaction valued the company at approximately $2 billion and provided capital for expansion. Alvogen has remained a privately held entity since its inception, with no public listing or . In 2025, Alvogen's shareholders agreed to sell the company to Pharmaceutical Co., Ltd., a Taiwan-based firm, in a deal announced on September 23, 2025, and expected to close by the end of 2025; upon completion, the acquisition will integrate Alvogen's assets into Lotus's operations, forming a specialized platform in generics and specialty pharmaceuticals.

History

Early development

Alvogen was established in 2009 as a pharmaceuticals company, leveraging the established manufacturing infrastructure of in , which provided a foundation for its initial production capabilities. Under the leadership of , who assumed the role of Chairman and CEO that year, the company prioritized rapid international expansion to build a global footprint in generics. A key early strategic move was the launch of operations in , with the opening of a office in December 2009 dedicated to product commercialization, sourcing of active pharmaceutical ingredients and finished , and forging partnerships across the region to support and entry efforts. In its formative years, Alvogen focused on product and , particularly in . By 2011, the company introduced an over-the-counter (OTC) product line in branded as "Pure ," targeting consumer health segments and establishing an early presence in one of the world's largest pharmaceutical markets. This launch complemented broader efforts in , including partnerships such as the multi-year with Par Pharmaceutical in 2009 for high-value, first-to-file opportunities, which bolstered the for generics. These initiatives addressed initial challenges in scaling commercialization in diverse regulatory environments while capitalizing on cost-effective sourcing from . Domestically, Alvogen invested in building its U.S. operations through team expansion and facility integration. The company opened a dedicated center in Pine Brook, , in 2010 to advance complex generic formulations, integrating it with the Norwich manufacturing site to streamline production and . This internal buildup enabled the launch of Alvogen's first products in the U.S. market in 2011, with the sales team achieving record performance that year through targeted generic offerings. By focusing on efficient generic development and leveraging Norwich's legacy expertise, Alvogen attained initial revenue milestones, underscoring its early operational momentum despite the competitive pressures of the generics sector.

Global expansion and acquisitions

Alvogen significantly expanded its international footprint in the early , opening offices in key European markets including , , , , , and by 2011, which facilitated entry into and beyond. By 2015, this growth had propelled the company to operations in 35 countries worldwide, supported by strategic investments from and that provided the capital for accelerated scaling. A pivotal move in 2015 was Alvogen's acquisition of a product portfolio from for the U.S. market, encompassing approved injectable products Clindamycin and , along with pending Abbreviated New Drug Applications (ANDAs) for and injections. This deal, part of 's divestitures to address antitrust concerns in its merger with , strengthened Alvogen's position in sterile injectables and marked a key step in its U.S. commercialization efforts. To enhance its offerings in and complex generics, Alvogen pursued strategic partnerships and in-licensing agreements during this period, building on earlier collaborations such as the 2012 partnership with for (Inflectra) in . These initiatives focused on high-barrier products, enabling Alvogen to leverage external R&D and expertise for global market entry. The combined impact of these expansions and deals drove substantial revenue growth, with Alvogen achieving over $1.1 billion in global revenues by 2017, primarily fueled by broadened commercial operations across its international network.

Recent developments (2018–2025)

In March 2025, Alvogen completed a comprehensive , raising $553 million in first-lien term loans due 2028 and $116 million in second-lien term loans due 2029 to support ongoing operations. On September 23, 2025, Alvogen announced its sale to Pharmaceutical Co., Ltd., creating a leading international specialized generics platform; the transaction, advised by , involved Lotus acquiring 100% equity in New Alvogen Group Holdings, Inc., positioning the combined entity as a top 20 global specialty pharma company.

Leadership and governance

Key executives

Lisa Graver serves as the of Alvogen, having joined the company in 2010 with over 20 years of experience in the , initially overseeing strategic operations in the market before her promotion to CEO following Robert Wessman's transition from the role in 2022. Under her leadership, Alvogen has focused on expanding its generics portfolio and navigating key transactions, such as the 2025 sale to Pharmaceuticals. Robert Wessman, the founder of Alvogen in 2009, acted as CEO until 2022, after which he transitioned to the position of Chairman while maintaining significant influence over the company's strategic direction as a major stakeholder. His ownership stake shapes executive decisions, particularly in global expansion and partnerships. Among other key executives, Christina Siniscalchi holds the role of Chief Quality Officer, bringing over a decade of senior experience from Alvogen's operations, including oversight of manufacturing sites. Carl Turner serves as Senior Vice President of Supply Chain, leading supply planning and third-party networks since joining in 2022. Dr. Shilpi Dhawan is Vice President-Clinical, responsible for clinical strategies and operations in complex generics development since December 2020. Early executive appointments between 2008 and 2010 laid the foundation for Alvogen's growth, including as in August 2009, with prior experience at and , and Elin Gabriel as in May 2010, leveraging her background in manufacturing from and .

Board of directors

Following the 2015 acquisition of a controlling stake by a consortium led by , including , Alvogen's incorporated representatives from these major investors to provide strategic guidance on global operations and growth initiatives. These investor-appointed members help oversee the company's expansion in complex generics and biosimilars, drawing on the consortium's expertise in pharmaceuticals. Róbert Wessman serves as Chairman of the board, a role that maintains continuity from Alvogen's founding in , where he developed the initial business strategy and led its early growth into a multinational generics firm. Wessman's leadership on the board emphasizes innovation in challenging-to-manufacture products, such as injectables and ophthalmics. Arni Hardarson, a director since , contributes legal and tax expertise from prior roles at and , supporting the board's focus on international structuring and compliance. The board also includes independent directors who prioritize , regulatory adherence, and opportunities for geographic diversification, ensuring balanced oversight in a competitive generics market. Key executives, including CEO Lisa Graver, report directly to the board for alignment on operational and strategic decisions. In response to the announced September 2025 acquisition of Alvogen by Pharmaceutical, the board is expected to evolve to facilitate , leveraging members' specialized knowledge in generics to strengthen the combined entity's portfolio in complex and branded products across and global markets. This structure positions the board to guide the new platform's emphasis on high-barrier generics, with Wessman continuing as Chairman of both Alvogen and .

Operations

Manufacturing capabilities

Alvogen maintains four manufacturing facilities across the globe, with sites in the United States, , and to support its production needs in key markets. The U.S. facility in , focuses on generics and injectables, leveraging established infrastructure for solid oral dosage forms such as tablets, capsules, and liquids. In and , the facilities cater to production demands, enabling localized manufacturing of pharmaceutical products. The company's manufacturing capabilities encompass a range of finished , with particular expertise in complex injectables, products, peptides, and 505(b)(2) formulations. These technologies allow Alvogen to produce high-value items that require advanced processes, such as long-acting injectables and specialized delivery systems. Alvogen's in-house production capacity supports over 30 products, prioritizing difficult-to-manufacture generics and specialty pharmaceuticals to meet global demand efficiently. This infrastructure underscores the company's emphasis on scalable, high-barrier manufacturing for competitive markets. Manufacturing operations form a core part of Alvogen's workforce, contributing to its 660 full-time equivalents and approximately 2,800 employees worldwide.

International offices and presence

Alvogen maintains its global headquarters in , serving as the primary hub for its operations with a strategic focus on North American markets. The company employs 660 full-time equivalents (FTEs) , supporting administrative, commercial, and research functions across its domestic facilities. In September 2025, Alvogen was acquired by Pharmaceutical, enhancing its integration with Asian manufacturing and global partnerships. The firm operates activities in over 30 countries, emphasizing , , and strategic partnerships to expand its pharmaceutical reach. Overall, Alvogen employs approximately 2,800 individuals worldwide, reflecting its broad international footprint. Alvogen's Asian presence is anchored by key hubs, notably in , where its subsidiary Alvogen Korea is headquartered in with around 605 employees dedicated to regional commercialization. Additional operations extend to and , bolstering distribution and partnerships in the region. This structure underscores significant employee concentration in , complementing the U.S. workforce.

Products and portfolio

Core product categories

Alvogen's product portfolio centers on generics as its foundational category, encompassing oral solids such as tablets, capsules, and suspensions, as well as topicals including creams, ointments, and transdermals, spanning therapeutic areas like , , respiratory , and . These generics emphasize niche formulations, including controlled-release and modified-release options, aimed at providing high-quality, cost-effective alternatives to branded drugs to enhance global healthcare accessibility. With a focus on first-to-file and first-to-market opportunities, this category forms the core of Alvogen's strategy to address high-volume, essential needs in diverse markets. In the realm of complex products, Alvogen targets high-barrier markets through injectables, including long-acting formulations in pens and vials, devices, and peptides, which require advanced development to meet stringent regulatory and technical demands. These products are strategically positioned for and alternative site administration, prioritizing innovation in delivery systems to differentiate in competitive segments. Alvogen's approach here leverages partnerships and in-house expertise to navigate the complexities of sterile manufacturing and challenges inherent to these formats. Alvogen's branded and over-the-counter (OTC) offerings, managed through subsidiaries like Almatica Pharma, include specialized lines in areas such as , anti-infectives, cardiovascular health, and , with examples like the "Pure Iceland" OTC line launched in . These products often incorporate 505(b)(2) pathways, which blend generic equivalents with innovative elements from branded references to extend market exclusivity and value. This category supports Alvogen's diversification into consumer-accessible therapeutics, emphasizing targeted commercialization in select regions. Alvogen's biosimilars efforts, primarily through its affiliate Alvotech, involve in-licensing and commercialization of alternatives targeting cancer, autoimmune diseases, inflammatory conditions, and related indications. This strategic emphasis, with development and handled by Alvotech, aims to provide affordable biologic options through rigorous clinical comparability studies, aligning with global trends toward biosimilar adoption to lower costs. Overall, Alvogen maintains a portfolio of over 50 products across these categories as of 2025, underscoring its commitment to a balanced mix of accessible and specialized pharmaceuticals.

Strategic acquisitions and developments

In 2015, Alvogen acquired a portfolio of four pharmaceutical products from for the U.S. market to support its expansion in generics, including two approved abbreviated new drug applications (ANDAs) for Clindamycin injection and solution, as well as two pending ANDAs for injection and injection, which provided exclusivity opportunities upon approval. This deal, valued as part of 's divestitures amid its merger, strengthened Alvogen's injectables category by adding hospital-based therapies for bacterial infections, respiratory conditions, antifungal treatment, and oncology support. Alvogen developed Bonsity (teriparatide injection), a branded specialty product approved by the FDA in 2020 for treating osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and those at high risk for fractures. This parathyroid hormone analog stimulates bone formation and is administered subcutaneously as a daily injection, positioning it as an alternative to existing therapies like Forteo for patients intolerant to other options. Bonsity's launch expanded Alvogen's portfolio into anabolic osteoporosis treatments, with ongoing availability in prefilled pen devices for improved patient compliance. In 2019, Alvogen launched its generic equivalent to Suboxone sublingual film, containing and , indicated for maintenance treatment of opioid dependence as part of a comprehensive program including counseling. Available in strengths such as 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, this AB-rated product offers a dissolvable to deter and enhance for management. The introduction addressed growing demand in addiction treatment, partnering with entities like Lotus Pharmaceuticals for U.S. commercialization. In September 2025, Pharmaceutical acquired Alvogen, creating a leading international platform for specialized generics. This transaction integrates Alvogen's portfolio of complex products, including , long-acting injectables, peptides, and 505(b)(2) offerings, with Lotus's over 250 commercial products and more than 100 development projects, enhancing global reach in , complex generics, and biosimilars. The deal positions the combined entity as a top-20 specialty pharmaceutical company, with Alvogen's U.S. operations, including manufacturing in , supporting expanded commercialization. Alvogen maintains ongoing research and development efforts in biosimilars via Alvotech and complex generics, building on historical milestones such as over 60 ANDA filings in in 2015 and a 2012 biosimilar agreement with that enabled entry into biologics markets in . Recent activities, including the 2025 acquisition, continue to prioritize 505(b)(2) applications and candidates to build durable revenue streams beyond standard generics.

Financial performance

Revenue and growth metrics

Alvogen, as a , does not publicly disclose detailed , which limits comprehensive access to its data; however, reports from credible analyses and company announcements provide key insights into its financial trajectory. The company began operations with revenues under $30 million in its early years around 2009–2010, scaling to over $400 million by 2014 through initial market entries and organic expansion. By 2015, annual reached $750 million, reflecting a of approximately 76% over the prior six years, driven primarily by organic development. This momentum continued, with Alvogen achieving global revenues exceeding $1 billion for the first time in , marking a significant milestone in its growth from a niche generics player to a multinational entity. Prior to , the company reported six consecutive years of strong profit growth alongside revenue increases, underpinned by consistent double-digit annual performance since its founding in 2009. Recent estimates place annual revenue at approximately $945 million, indicating sustained operations amid a maturing , though exact figures remain opaque due to its status. Key drivers have included geographic expansion to 35 countries, enabling broader and diversified streams, as well as the launch of complex products and scale-up of capabilities to meet rising demand. Employee headcount has paralleled this progress, growing to 2,800 by and correlating with operational expansions that supported gains. Overall, Alvogen has maintained reported double-digit annual rates in , positioning it as one of the faster-expanding players in the global generics sector.

Major investments and transactions

Alvogen's early development was supported by GMS Capital Partners, which in acquired Norwich Pharmaceuticals—a in —for an undisclosed amount when the target had under $30 million in annual revenues, laying the foundation for Alvogen's launch as a U.S. generics . In 2010, Alvogen secured additional private to fuel international expansion, establishing offices in over 20 emerging markets across , , and without pursuing public equity offerings. A pivotal transaction occurred in 2015 when a consortium led by , including and Vatera Healthcare Partners, acquired a controlling stake from Capital Management in a deal valuing Alvogen at $2 billion; this investment enabled accelerated acquisitions and substantial R&D commitments, including over $500 million for biosimilars and manufacturing enhancements. Following the 2015 deal, Alvogen achieved robust revenue growth, with annual turnover surpassing $1.1 billion by the late , reflecting a of approximately 76% in the preceding years. In September 2025, Pharmaceutical Co., Ltd. announced the acquisition of Alvogen's operations (New Alvogen Group Holdings, Inc.) in a with an value of up to $2 billion, including , preferred shares, and contingent earnouts, expected to close in the fourth quarter of 2025. Post-closing, pro forma combined revenues and EBITDA for are expected to double, integrating the operations to form an enhanced platform for specialized generics with strengthened global , particularly in the and .

Legal and regulatory issues

Patent litigation

Alvogen's subsidiary Norwich Pharmaceuticals faced a significant setback in 2024 when the U.S. denied its petition for in a patent dispute with Salix Pharmaceuticals (a subsidiary) over generic versions of Xifaxan (), used to treat and . The case stemmed from Norwich's (ANDA) filing, which Salix alleged infringed multiple s covering the drug's use in patients. The Federal Circuit had previously affirmed the district court's ruling that Norwich's generic would infringe valid claims of the patents, leading to an injunction blocking FDA approval until patent expiry. In April 2025, the U.S. District Court for the District of Columbia granted in favor of the FDA, Salix, and against , denying Norwich's motion for final approval of its ANDA and closing the case, thereby upholding the block on generic entry until at least 2028. Since 2017, Alvogen has been embroiled in ongoing litigation with over Suboxone film, a product for treatment. accused Alvogen of infringing multiple U.S. patents, including Nos. 9,687,454, 9,931,305, 9,765,045, and others covering the film's formulation, dosage, and delivery method, following Alvogen's ANDA submission for a version. Alvogen countered with antitrust claims, alleging engaged in monopolistic practices through thickets and pay-for-delay settlements to delay entry. The case has seen partial rulings, including a 2019 Federal Circuit decision affirming non-infringement on certain drying process claims, but remains active with motions and appeals as of late 2024. In the 2024 Pharmacyclics LLC v. Alvogen Pine Brook LLC case, Alvogen challenged patents related to , the active ingredient in Imbruvica, a treatment for certain blood cancers, through an ANDA for generic tablets. (an subsidiary) asserted 18 patents, but the U.S. District Court for the District of granted of non-infringement on 17 of them and, after a , found non-infringement of the remaining U.S. No. 10,335,462 due to failure to meet specific concentration limitations for p-cyclodextrin. The Federal Circuit affirmed these non-infringement findings in a related 2022 appeal on validity, while a separate 2024 district court decision upheld infringement of one other patent but denied ' request for attorney fees, reflecting Alvogen's partial success in limiting the scope of enforceable claims. Alvogen secured a key victory against Persion Pharmaceuticals in a 2019 Federal Circuit decision (affirmed from a district court ruling) concerning U.S. Nos. 9,265,760 and 9,339,499, which claimed methods for treating pain in patients with mild or moderate hepatic impairment using extended-release formulations without dose adjustment. Persion alleged infringement by Alvogen's ANDA for a Zohydro . The court found the patents obvious over , including inherent properties of metabolism in hepatic impairment, and affirmed non-infringement, allowing Alvogen to proceed without liability. No further 2023 Federal Circuit developments were identified in this dispute, though related hepatic impairment patent issues appeared in Alvogen's other litigations.

Other controversies and settlements

In April 2025, Alvogen reached a nationwide settlement agreement with multiple U.S. states and local governments to resolve claims related to its marketing and distribution practices of medications, which were alleged to have contributed to the opioid crisis. The agreement, part of a broader $720 million resolution involving eight pharmaceutical companies, required Alvogen to make remediation payments and implement injunctive relief measures, including restrictions on future promotion, without admitting liability. Between 2018 and 2020, Alvogen initiated legal action against the state of to prevent the use of its product in lethal injections for executions, citing the state's alleged deceptive acquisition of the drug in violation of Alvogen's distribution policies. In July 2018, a Nevada district court granted a temporary blocking an upcoming execution and ultimately ruled in Alvogen's favor after finding evidence of bad faith by state officials, prohibiting the use of the drug for . The matter concluded in July 2020 when agreed to return the remaining supply of to Alvogen, resolving the dispute without further escalation. In July 2025, the High Court overturned a 2022 decision by the Fair Trade Commission (KFTC) that had accused Alvogen Korea of engaging in anti-competitive practices through an agreement with to delay generic entry into the market for the cancer drug Iressa (). The court ruled in favor of Alvogen, determining that the KFTC's allegations of lacked sufficient evidence to establish a violation of laws, thereby nullifying the imposed fine of approximately 1.5 billion (about $1.1 million USD at the time). This decision highlighted challenges in enforcing antitrust measures in South Korea's pharmaceutical sector. Alvogen has maintained general across its global operations in over 35 countries, with no significant fines or enforcement actions reported beyond the aforementioned settlements and the resolved Korean matter.

References

  1. [1]
    Company - Alvogen
    Alvogen is a privately owned US-based company focused on developing, in-licensing, manufacturing and marketing pharmaceutical products.
  2. [2]
    Highlights and Milestones from Alvogen's History
    Alvogen was founded in 2009, expanded internationally in 2010, first sold products in the US in 2011, and launched first generic Exelon patch in 2015.
  3. [3]
    Meet Róbert Wessman - Alvogen
    Róbert founded Alvogen in 2009, serving as CEO until 2022, and continues as chairman today. Having sketched the business plan on a restaurant napkin.Missing: Norwich | Show results with:Norwich
  4. [4]
    Norwich Pharma Services 2025 Company Profile - PitchBook
    Norwich Pharma Services was acquired on 03-Aug-2007. Who acquired Norwich Pharma Services? Norwich Pharma Services was acquired by Alvogen Group. Data ...
  5. [5]
    Our vision - Alvogen
    A unique portfolio of high-quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy.
  6. [6]
    Purpose - Alvogen
    Our true purpose as a company is to make people's lives better by producing high quality medicines that help people live longer, healthier and more active ...
  7. [7]
    The story of Alvogen and the founding of a pharma empire
    Founded in 2009, the company now has an annual turnover that exceeds $1.1bn, producing 350 pharmaceutical products for various markets across the globe.
  8. [8]
    Offices - Alvogen
    Morristown, NJ Headquarters. 44 Whippany Road, Suite 300 Morristown, NJ 07960 ; Pine Brook, NJ R&D facility. 10 Bloomfield Ave, Building B, Suite 2, Pinebrook, ...
  9. [9]
    CVC and Temasek to buy $2billion generic drugs firm Alvogen
    Jun 22, 2015 · Wessman sold a stake in Alvogen to the private equity fund Pamplona in 2014. The new owners also include U.S. investment group Vatera Healthcare ...
  10. [10]
    CVC leads investment consortium to acquire controlling stake in ...
    Jun 22, 2015 · The stake has been acquired from Pamplona Capital Management ("Pamplona"). Aztiq Pharma, the investment vehicle led by Robert Wessman, Alvogen's ...Missing: ownership | Show results with:ownership
  11. [11]
    CVC, Temasek Buy Pamplona's $2-Billion Drugmaker Alvogen
    Jun 22, 2015 · A group including CVC Capital Partners and Singapore's Temasek Holdings Pte bought a controlling stake in Alvogen in a deal that values the US drugmaker at ...
  12. [12]
    Alvogen Announces Sale to Lotus, Creating a Leading International ...
    Sep 23, 2025 · [23rd September 2025]. Alvogen Pharma US, Inc. (“Alvogen”), a privately owned US-based pharmaceutical company, today announced a definitive ...Missing: date | Show results with:date
  13. [13]
    Lotus Pharmaceutical to Acquire Alvogen US, Creating a Top 20 ...
    Sep 24, 2025 · Lotus Pharmaceutical to Acquire Alvogen US, Creating a Top 20 Global Specialty Pharma Powerhouse · Taipei, Taiwan, 24 September 2025 · Leadership ...Missing: Norwich date
  14. [14]
    Alvogen Launches Asia Operations
    Dec 15, 2009 · Alvogen, Inc. (Alvogen), the US-based pharmaceutical company, today announced that it has established operations in Asia and has opened an office in Shanghai, ...Missing: history | Show results with:history
  15. [15]
    Alvogen acquires research and development capabilities and enters ...
    Oct 22, 2009 · Alvogen acquired R&D from Par, entered a multi-year deal for generic product development, and will develop difficult to replicate drugs ...
  16. [16]
    Alvogen opens new R&D center of excellence
    Jun 14, 2010 · Alvogen has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products.Missing: buildup integration
  17. [17]
    Alvogen to Acquire Product Portfolio from Pfizer for the U.S. market
    Aug 25, 2015 · In addition, Alvogen will acquire two pending ANDAs, Voriconazole injection and Melphalan injection. Both pending applications represent ...
  18. [18]
    Because of Hospira Merger, Pfizer Sells Off 4 Drugs to Alvogen
    Aug 26, 2015 · Pine Brook, NJ-based Alvogen announced today that it acquired four drug products from Pfizer Inc. The compounds bought are three injectable drugs and one ...
  19. [19]
    Meet our management - Alvogen
    Lisa joined Alvogen in 2010 and serves as the CEO of Alvogen's business. She has worked in various leadership roles in the pharmaceutical industry for the past ...Missing: buildup early
  20. [20]
    Alvogen Announces Sale to Lotus, Creating a Leading International ...
    Sep 23, 2025 · MORRISTOWN, N.J., Sept. 23, 2025 /PRNewswire/ -- Alvogen Pharma US, Inc. ("Alvogen"), a privately owned US-based pharmaceutical company, ...Missing: date | Show results with:date
  21. [21]
    Alvogen to be acquired by Lotus - Chain Drug Review
    Alvogen Pharma US, Inc. has entered into a definitive agreement for its shareholders to sell the company to Lotus ...
  22. [22]
    Alvotech Appoints Interim Chief Quality Officer | Nasdaq
    Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as ...
  23. [23]
    Dr. Shilpi Dhawan - Vice President-Clinical at Alvogen | The Org
    Currently serving as Vice President of Clinical at Alvogen since December 2020, Dr. Dhawan is responsible for developing clinical strategies for complex ...
  24. [24]
    Alvogen appoints three new top executives
    Mar 30, 2008 · Alvogen Inc. the US-based generic pharmaceutical company, today announces that three new top executives have joined its Executive Board.Missing: early | Show results with:early
  25. [25]
    Arni Hardarson - Deputy to the CEO - Alvogen
    Arni Hardarson is a director and Deputy to the CEO at Alvogen. He previously worked at Deloitte and Actavis, and holds a Master's degree in Law.
  26. [26]
    Manufacturing facility - Alvogen
    Alvogen is headquartered in Morristown, New Jersey with significant inhouse manufacturing capacity in Norwich, NY. Alvogen is built on the strong foundation ...
  27. [27]
    Alvogen
    Róbert founded Alvogen in 2009, serving as CEO until 2022, and continues as chairman today. Having sketched the business plan on a restaurant napkin, he ...Meet Róbert Wessman · Products · Join us · Manufacturing facility
  28. [28]
    Alvogen Announces Sale to Lotus, Creating a Leading International ...
    Sep 23, 2025 · Alvogen is growing its portfolio of complex, high value products including inhalation, long acting injectables, peptides and strategic 505(b)(2) ...
  29. [29]
    CVC to Explore Options for $4 Billion Drugmaker Alvogen - Bloomberg
    Sep 26, 2017 · It operates a manufacturing facility in Norwich, New York under the Norwich Pharmaceuticals brand. Alvogen has 350 marketed products ...
  30. [30]
    Alvogen - LinkedIn
    Apr 7, 2025 · Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and ...
  31. [31]
    Alvogen Company Overview, Contact Details & Competitors | LeadIQ
    As of September 2025, Alvogen has approximately 482 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Executive ...Missing: total | Show results with:total
  32. [32]
    Alvogen - Overview, News & Similar companies | ZoomInfo.com
    Headquarters. 44 Whippany Rd Ste 300, Morristown, New Jersey, 07960, United States ; Phone Number. (973) 796-3400 ; Revenue. $945.2 Million ...
  33. [33]
    Alvogen Korea 2025 Company Profile - PitchBook
    Alvogen Korea is headquartered in Seoul, South Korea. What is the size of Alvogen Korea? Alvogen Korea has 605 total employees. What industry is Alvogen Korea ...
  34. [34]
    Products - Alvogen
    A unique portfolio of high quality and difficult-to-make pharmaceutical products fuels our targeted growth strategy. We offer high-quality, ...US Product catalog · Biosimiliars · Patient safety · Manufacturing facility
  35. [35]
    Setting a New Standard in Biosimilars - Alvogen
    Release. Partnership through Alvogen and key global players will be used to bring biosimilars to patients around the world.
  36. [36]
    Alvogen to buy product portfolio from Pfizer - The Pharma Letter
    Aug 27, 2015 · Generic drug company Alvogen said it has agreed to buy a portfolio of four pharmaceutical products, in the US from pharma giant Pfizer ...<|control11|><|separator|>
  37. [37]
    Alvogen to acquire 4 Pfizer products - Drug Store News
    Aug 28, 2015 · Alvogen will acquire three injectable products and one inhaled solution product, the company said. Two of the products, clindamycin injection ...
  38. [38]
    BONSITY (teriparatide injection)—Anabolic therapy for osteoporosis
    To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available ...
  39. [39]
    Teriparatide Injection - Alvogen
    For more information on this product, please go to www.AlvogenTeriparatide.com. NDC#, 47781-0652-89. Strength, 560 mcg/2.24 mL (250 mcg/mL) 20 mcg per dose.
  40. [40]
    Alvogen Launches Generic Equivalent to Suboxone ...
    Feb 20, 2019 · Alvogen has launched its generic equivalent to Suboxone® sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the US.
  41. [41]
    Buprenorphine and Naloxone Sublingual Film C-III - Alvogen
    Buprenorphine and Naloxone Sublingual Film C-III. AB rated to: Suboxone®*. NDC#, 47781-355-03. Strength, 2 mg/0.5 mg. PKG size, 30. GCN, 28958.
  42. [42]
    BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM - DailyMed
    Buprenorphine and naloxone sublingual film is indicated for treatment of opioid dependence. Buprenorphine and naloxone sublingual film should be used as part of ...
  43. [43]
    Alvogen and Lotus confirmed launch of Buprenorphine and ...
    Feb 20, 2019 · The product comes in 4 strengths (2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg) and is a generic equivalent of Suboxone® sublingual film.
  44. [44]
    CVC Capital Partners leads investment consortium to acquire ...
    Jun 22, 2015 · A consortium led by CVC Capital Partners, including Temasek and Vatera, acquired a controlling stake in Alvogen from Pamplona Capital ...
  45. [45]
    Alvogen - GMS Capital Partners
    Specialty Pharmaceuticals ... Founded Alvogen and launched a US generics platform. 2009. Partnered with new management team led by Robert Wessman, former CEO of ...
  46. [46]
    Alvogen CEO recognized by European CEO Magazine
    Jun 11, 2018 · Last year, Alvogen posted global revenues exceeding US$1bn for the first time, while sister company, Alvotech, is in a great position to ...
  47. [47]
    Alvogen Pharma US Inc. Ratings Affirmed On Generi - S&P Global
    Dec 23, 2020 · Alvogen develops complex generic and branded generic products to generate more durable revenue streams than standard generics (i.e., small ...Missing: 2010 | Show results with:2010
  48. [48]
    Alvogen completes funding for further growth
    Nov 19, 2010 · Offices around the world – Alvogen has identified over 20 emerging markets in Europe, Asia and Latin America as its priorities for entry.Missing: rounds | Show results with:rounds
  49. [49]
    Lotus grows its US generics business with acquisition of Alvogen
    Sep 26, 2025 · Alvogen is based in New Jersey and was established by Wessman in 2009 when he and his investors bought out Norwich Pharmaceuticals to gain its ...Missing: date | Show results with:date<|control11|><|separator|>
  50. [50]
    US Supreme Court declines to hear patent dispute over Bausch ...
    Nov 18, 2024 · The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based ...Missing: denial | Show results with:denial
  51. [51]
    Justices Deny Norwich Challenge of Generic Xifaxan Injunction
    Nov 18, 2024 · Norwich had argued the lower court ruling improperly delayed approval of a generic drug for a use that doesn't infringe valid patents and urged ...
  52. [52]
    INDIVIOR INC. et al v. ALVOGEN PINE BROOK, INC., No. 2 ...
    Aug 24, 2020 · Indivior's Suboxone film is also covered by Patent No. 8,603,514 ... and Alvogen claiming infringement of the new '305 Patent. (See 2 ...Missing: ongoing | Show results with:ongoing
  53. [53]
    Federal Circuit Mostly Affirms Suboxone Generics Do Not Infringe ...
    Jul 15, 2019 · Reddy's and Alvogen do not infringe one of Indivior's patents because their versions of Suboxone Film are dried in a different way than is ...<|separator|>
  54. [54]
    Pharmacyclics LLC v. Alvogen Pine Brook LLC - Robins Kaplan LLP
    Apr 30, 2024 · Alvogen filed an ANDA with FDA seeking approval to market generic ibrutinib tablets. Pharmacyclics filed suit, alleging patent infringement of 18 patents.
  55. [55]
    Pharmacyclics Can't Score Fees After Imbruvica Patent Win - Law360
    Apr 30, 2024 · The judge held that the defendants infringed one patent and that the patent as well as several others weren't invalid. The Federal Circuit ...
  56. [56]
    Federal Circuit Affirms Axinn's Trial Victory for Alvogen
    Persion sued Alvogen for patent infringement over two patents claiming methods of treating patients that have mild or moderate hepatic impairment with an ...Missing: 2023 | Show results with:2023
  57. [57]
    [PDF] ALVOGEN SETTLEMENT AGREEMENT
    Jul 25, 2025 · ALVOGEN SETTLEMENT AGREEMENT. This Settlement Agreement, dated as of April 4, 2025 (the “Agreement”), sets forth the terms of.
  58. [58]
    https://www.axinn.com/en/insights/news/Federal_Circuit_Affirms_Axinn_Trial_Victory_Alvogen
  59. [59]
    Nevada Agrees to Return Supply of Execution Drugs to Manufacturers
    Jul 23, 2020 · In July 2018, Alvogen Pharmaceuticals, a producer of the sedative midazolam, filed a lawsuit against the state, requesting a temporary ...
  60. [60]
    Judge blocks Nevada execution - rules that state may not use ...
    Jul 11, 2018 · Judge Elizabeth Gonzalez decided in the company's favor. Her ruling: “The state is restrained and enjoined from using midazolam.”
  61. [61]
    Seoul High Court rules in favour of Alvogen Korea and overturned ...
    Jul 4, 2025 · Alvogen Korea has received a written judgement from the Seoul High Court, ruling in favour and overturned allegations by the Korea's Fair-Trade Commission of ...